(function(doc, html, url) {
var widget = doc.createElement("div");
widget.innerHTML = html;
var script = doc.currentScript; // e = a.currentScript;
if (!script) {
var scripts = doc.scripts;
for (var i = 0; i < scripts.length; ++i) {
script = scripts[i];
if (script.src && script.src.indexOf(url) != -1) break;
}
}
script.parentElement.replaceChild(widget, script);
}(document, '
A new anthelmintic salt
What is it about?
In this work, we present the design, synthesis and chracterization of a mebendazole (MBZ) salt aiming to obtain a new material incorporating the drug and avoiding polymorph interconversion and exhibiting a solubility and dissolution profile similar to those of the MBZ therapeutically preferred form C. This salt crystallizes in the monoclinic P21/c (No. 14) space group. A detailed study of the crystal structure performed by atom-to-atom and global Hirshfeld surface analysis indicates that several hydrogen bonds act as the main intermolecular interactions stabillizing the material.
Why is it important?
We obtained a new mebendazolium dihydrogen phosphate phosphoric acid compound. This material can be considered as an ionic cocrystal (i.e., a cocrystal of a salt), since the phosphoric acid molecules are connected with the ionic components of the salt through non-covalent interactions (i.e., hydrogen-bonds). Phosphoric acid and its anions are approved coformers by the Food and Drug Administration (FDA), which could make this new material suitable for pharmaceutical formulations. The new material is stable up to 185 °C.